Skip to content

Microdosing: all studies

Page 52 of 56: studies 511 to 520 of 555, newest first. Back to the microdosing overview

Research

Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT

Psychopharmacology January 22, 2022 Steven A. Barker 59 citations

As with all drugs, the route, form, and/or dose of a substance administered or applied can play a defining role in its overall pharmacology and use as a therapeutic. This review will focus on these factors as they relate to the psychedelic N,N-dimethyltryptamine (DMT). It will examine the positive and negative aspects of different formulations and routes of administration of DMT and the...

DOI: 10.1007/s00213-022-06065-0 (opens in new tab) Full text (opens in new tab) Pharmacology Hallucinogen Monoamine oxidase inhibitor Oral administration +2

Subject in the Making: Technologies of the Self and Aspirations for a Good Life in Contemporary Denmark.

Medical Anthropology 2022 Margit Anne Petersen, Aja Smith, Dorthe Brogaard Kristensen et al. 12 citations

Coping with crisis is fundamental for human life, but so is the pursuit of everything good and fruitful. We revisit Foucault's technologies of the self as an analytical lens for what people do when pursuing a good life in contemporary Denmark. Comparing three emerging self-improvement domains; psychedelic micro-dosing, meditation and mindfulness, and fitness self-tracking, we explore processes...

DOI: 10.1080/01459740.2022.2054716 (opens in new tab) Full text (opens in new tab) Denmark Fitness self-tracking Psychedelic micro-dosing Self-enhancement +2

Raising awareness: The implementation of medical cannabis and psychedelics used as an adjunct to standard therapy in the treatment of advanced metastatic breast cancer

Drug Science, Policy and Law 2022 Rayyan Zafar, Dustin Sulak, Jaime Brambila et al. 3 citations

A 49-year-old woman was diagnosed with an ER + , PR-, HER2 + , BRCA- invasive ductal carcinoma which progressed metastatically to include bone, liver, and lymph node involvement. Standardised care included a 26-month treatment period with targeted chemotherapy and a ketogenic diet. The patient also began a course of cannabinoid-based therapy, consisting initially of a titrated high-dose...

New trends in pharmacological control of neuropsychiatric symptoms of dementia.

Current opinion in pharmacology December 2021 Damiana Scuteri, Maria Tiziana Corasaniti, Paolo Tonin et al.

Abnormal neuronal and synaptic plasticity occurs in Alzheimer's disease (AD) and depression. The latter, particularly late-life, has been recognized as fundamental in the identification of at-risk prodromal stages of AD. The lack of disease-modifying drugs and the off-label use of antipsychotics and antidepressants for neuropsychiatric symptoms (NPSs) have caused a season of therapeutic...

Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers

Scientific Reports November 18, 2021 Joseph M. Rootman, Pamela Kryskow, Kalin Harvey et al. 78 citations

Abstract The use of psychedelic substances at sub-sensorium ‘ microdoses’, has gained popular academic interest for reported positive effects on wellness and cognition. The present study describes microdosing practices, motivations and mental health among a sample of self-selected microdosers ( n = 4050) and non-microdosers ( n = 4653) via a mobile application. Psilocybin was the most commonly...

Synergistic Effect of Ketamine and Buprenorphine Observed in the Treatment of Buprenorphine Precipitated Opioid Withdrawal in a Patient With Fentanyl Use.

Journal of Addiction Medicine November 16, 2021 Christian Hailozian, Joshua Luftig, Amy Liang et al.

Optimal treatment of buprenorphine precipitated opioid withdrawal (BPOW) is unclear. Full agonist treatment of BPOW is limited by buprenorphine's high-affinity blockade at mu-opioid receptors (μORs). Buprenorphine's partial agonism (low intrinsic efficacy) at μORs can limit the effectiveness of even massive doses once BPOW has begun. Adjunct medications, such as clonidine, are rarely effective...

Psychedelic medicines for mood disorders: current evidence and clinical considerations

Current Opinion in Psychiatry November 15, 2021 Jerome Sarris, Diego Pinzon Rubiano, Kimberley Day et al. 12 citations

Purpose of review Despite advances in treatment modalities for mood disorders over recent decades, further therapeutic options are still required. Increased research is occurring, with the pursuit of psychedelic-based pharmacotherapies for a range of mood disorders and other conditions. Recent findings Serotonergic psychedelics have been found to modulate brain networks underlying various...

Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults

Psychopharmacology October 6, 2021 Conor H. Murray, Ilaria Tare, Claire Perry et al. 75 citations

Classical psychedelics, including psilocybin and lysergic acid diethylamide (LSD), are under investigation as potential therapeutic agents in psychiatry. Whereas most studies utilize relatively high doses, there are also reports of beneficial effects of “microdosing,” or repeated use of very low doses of these drugs. The behavioral and neural effects of these low doses are not fully understood....

Psychedelic Drugs and Atheism: Debunking the Myths

Religions August 8, 2021 Wayne Glausser 7 citations

Two recent surveys of people who took psychedelic drugs and reported “God experience encounters”, along with successful clinical trials using psychedelic therapy for depression, have given rise to public misconceptions about psychedelics and atheism. Specifically, three inferences have been drawn: (1) that the psychedelic experience tends to dissolve atheist convictions; (2) that atheist...

DOI: 10.3390/rel12080614 (opens in new tab) Atheism Mythology Epistemology Psychoanalysis +1

Dosed

Educational Media Reviews Online June 22, 2021 C. Healy

Distributed by Collective Eye Films, 1315 SE 20th Ave. #3, Portland OR 97214; 971-236-2056Produced by Tyler Chandler and Nichaols MeyersDirected by Tyler Chandler2019, Streaming, 84 mins Dosed is a Canadian documentary about a heroin addict named Adrianne. The film follows her through her long-term addictive behaviors, her family background and her attempts to break away from her addiction...